Perspective Therapeutics (CATX) Depreciation and Depletion (2014 - 2024)

Perspective Therapeutics has disclosed Depreciation and Depletion across 11 years of filings, most recently posting -$1.6 million for Q4 2024.

• Depreciation and Depletion for Q4 2024 came in at -$1.6 million, down 250.66% year-over-year; the trailing twelve-month figure through Sep 2025 was -$1.6 million (down 239.89% YoY), and the FY2023 annual result was $232000.0, down 13.11% from the prior year.
• Depreciation and Depletion came in at -$1.6 million for Q4 2024 at Perspective Therapeutics, down from $669000.0 in the prior quarter.
• In the past five years, Depreciation and Depletion ranged from a high of $669000.0 in Q3 2024 to a low of -$1.6 million in Q4 2024.
• The 5-year median for Depreciation and Depletion is $64000.0 (2022), against an average of $41526.3.
• Peak annual rise in Depreciation and Depletion reached 280.88% in 2023, while the deepest fall reached 427.54% in 2023.
• Perspective Therapeutics' Depreciation and Depletion stood at $37000.0 in 2020, then tumbled by 310.81% to -$78000.0 in 2021, then jumped by 276.92% to $138000.0 in 2022, then tumbled by 427.54% to -$452000.0 in 2023, then sank by 250.66% to -$1.6 million in 2024.
• The last three Depreciation and Depletion figures came in at -$1.6 million (Q4 2024), $669000.0 (Q3 2024), and $570000.0 (Q2 2024), per Business Quant data.